Key Takeaways
- Korea’s biotech sector is prominently featured at the BIO International Convention in San Diego, with several major companies seeking global partnerships.
- For the first time, an official session will focus on Korea’s rise as a biotech innovation hub, featuring key industry representatives.
- Korean firms like Samsung Biologics and Celltrion showcase advanced technologies and facilities to enhance their global market presence.
Korean Biotech Firms Showcase Innovation at BIO International Convention
Korean biopharmaceutical and biotechnology companies are gathering at the BIO International Convention in San Diego to pursue global expansion and partnerships. This year’s event marks substantial participation from Korea, with recognized leaders such as Samsung Biologics and Celltrion prominently featured.
Samsung Biologics, making its 14th appearance, plans to utilize a 140-square-meter booth to showcase its comprehensive service offerings. The company will highlight its recently acquired Rockville, Maryland facility, which has a drug substance capacity of 60,000 liters. This acquisition and its existing plant in Incheon bolster Samsung’s total manufacturing capacity to 845,000 liters, solidifying its status in the contract development and manufacturing organization (CDMO) sector.
Celltrion, appearing for the 17th time, is preparing to promote its current biosimilars and highlight its advancements in drug development, particularly in artificial intelligence (AI). A dedicated AI zone within its booth aims to demonstrate Celltrion’s commitment to evolving into a global drug developer beyond its biosimilar roots. The company aims to partner with global entities to leverage next-generation technologies, including AI-driven platforms for drug development.
Alongside these industry giants, SK Biopharmaceuticals will present within the event’s digital health and AI sector, underlining its initiatives in drug discovery and R&D digitization. The firm emphasizes patient-centered approaches in its development processes. Lotte Biologics will showcase its new plant in Songdo and the capabilities of its Syracuse facility in New York, emphasizing its dual-site manufacturing strategies.
A landmark session titled “Korea Rising: Don’t Be Late to Asia’s Next Innovation Hub” will be held for the first time, featuring representatives from several top biotech entities and organizations illustrating Korea’s burgeoning industry. The Korea Biotechnology Industry Organization (KoreaBio) will also present 51 biotechnology firms within its country pavilion during the convention, showcasing innovative pipelines and research achievements.
This year’s convention is expected to attract over 20,000 participants from more than 70 countries, positioning it as a key venue for investment and collaboration in the global biotech landscape. KoreaBio’s vice-chair, Lee Seung-gyu, remarked on the event’s potential as a “battleground” for biotech investments, pledging support for Korean firms in navigating opportunities with major pharmaceutical companies and investors.
The content above is a summary. For more details, see the source article.